Statins’ Tradeoff Between Heart Disease and Diabetes Can Be Avoided Says CBCD

Share Article

When patients take today’s drugs, there is always a tradeoff.

The Center for the Biology of Chronic Disease (CBCD) recently learned that the FDA has added new warning labels regarding side effects such as memory loss and diabetes to the bottles of popular drugs such as Lipitor and Torvast.

What do patients prefer, heart disease or diabetes? When they take statins, they have to choose. Surprised? They shouldn’t be. When patients take today’s drugs, there is always a tradeoff.

The CBCD believes tradeoffs are not a necessary evil. There is another way.

This tradeoff is the central theme in the debate between authors in the New York Times and Forbes magazines in regards to statins, with the Times writing a critical review of this tradeoff and Forbes responding with a more positive outlook.

Dr. Eric J. Topol, a cardiologist writing in the New York Times said, “We’re overdosing on cholesterol-lowering statins, and the consequence could be a sharp increase in the incidence of Type 2 diabetes.” [1]

As part of a response by Larry Husten, a medical journalist with Forbes magazine, Dr. C. Michael Minder, M.D. a doctor at Johns Hopkins said “What is clear is that high risk primary prevention patients stand to gain significant benefit from statin therapy, and the harms of new onset diabetes are outweighed by the reduction in cardiovascular morbidity and mortality.” [2]

So, should doctors and patients reject the trade-off between diseases when taking statins? Or, should they accept it? (E.G., you might not die from heart disease, but you will die from diabetes.)

The CBCD believes there is another way: neither reject or accept the tradeoff, but eliminate it altogether.

In contrast with the current paradigm held by pharmaceutical companies and the FDA, a paradigm that involves designing drugs that inhibit or stimulate one enzyme/protein/hormone and hoping that this enzyme/protein/hormone is involved in only a single bodily system, the CBCD urges the adoption of an evidence based, alternative view.

The CBCD proposes the adoption of Microcompetition, a theory that identifies the origin of many chronic diseases. Such diseases include atherosclerosis, multiple sclerosis, stroke, cancer, obesity, diabetes, lupus, thyroiditis, osteoarthritis, rheumatoid arthritis, and alopecia.

When doctors treat a symptom, such as lowering cholesterol, they aggravate or create all new symptoms elsewhere in the body such as memory loss and diabetes. In contrast, when doctors will treat the origin of the disease they will not only cure it, but also cure other seemingly unrelated diseases.

The CBCD encourages the FDA, doctors, biologists, virologists, and scientists to obtain a copy of “Microcompetition with Foreign DNA and the Origin of Chronic Disease” written by Dr. Hanan Polansky.

The CBCD believes Dr. Polansky’s findings may indeed be a huge blow to the paradigm held by the FDA and the entire pharmaceutical industry.

The book is available as a free download from the CBCD website. (http://www.cbcd.net )

"I found that the theory is groundbreaking and will likely open doors to many exciting research areas and treatment options ... biology and medicine lag behind and remain experimental disciplines, which are heavy on experimental data but thin on applicable theories that could guide future directions. In this sense, Dr. Polansky's book is nothing short of revolutionary." - Liqun Zhang, PhD - Research Associate, Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill

The CBCD endorses Dr. Polansky’s theory and invites scientists and the media to contact us for dialogue regarding the theory.

For more information on the Center for the Biology of Chronic Disease, or to schedule an interview with Dr. Polansky on the subject of Microcompetition with Foreign DNA, please visit http://www.cbcd.net or call 585-250-9999.

References:

[1] [2 http://www.forbes.com/sites/larryhusten/2012/03/05/statins-and-diabetes-real-concern-or-much-ado-about-nothing/

The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.

The CBCD published the “Purple” book entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” written by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between the DNA of latent (chronic) viruses and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

We invite biologists, virologists, and scientists everywhere to download Dr. Polansky's book here: http://cbcd.net/.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John S. Boyd, PhD
CENTER FOR THE BIOLOGY OF CHRONIC DISEASE
(585) 250-9999
Email >
Visit website